Clinical trial
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity…
NCT00272051 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00272051 |
|---|---|
| Title | XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy |
| Official title | A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastases, Colorectal Neoplasms, Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | SR57746A |
| Enrollment | 620 |
| Start date | Jul 1, 2002 |
| Completion | May 1, 2004 |
| First posted | Jan 4, 2006 |
| Last update posted | Sep 13, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: